Loading
A phase 3 trial of Rilvegostomig, Capecitabine and Gemcitabine + cisplatin in biliary tract cancer, run by AstraZeneca, active and no longer recruiting.
Rilvegostomig + Chemotherapy as Adjuvant Therapy for Biliary Tract Cancer After Resection (ARTEMIDE-Biliary01) is a phase 3 interventional study registered as NCT06109779 by AstraZeneca, with 760 participants enrolled, started 2023-12-04 and due to reach its primary completion in 2029-01-02. Interventions recorded: Rilvegostomig, Placebo, Capecitabine, Gemcitabine/Cisplatin and S-1 [Tegafur/Oteracil/gimeracil].
Shares Rilvegostomig, Gemcitabine + cisplatin, AstraZeneca, Biliary tract cancer (cholangiocarcinoma) and the tag pipeline.
Shares Rilvegostomig, Capecitabine, AstraZeneca and the tag pipeline.
Shares Rilvegostomig, AstraZeneca and the tag pipeline.
Shares Gemcitabine + cisplatin, AstraZeneca, Biliary tract cancer (cholangiocarcinoma) and the tag pipeline.
Shares Rilvegostomig, AstraZeneca, Biliary tract cancer (cholangiocarcinoma) and the tag pipeline.
Shares Rilvegostomig, AstraZeneca and the tag pipeline.
Shares Rilvegostomig, Capecitabine, AstraZeneca and the tag pipeline.
Shares Rilvegostomig, Capecitabine, AstraZeneca and the tag pipeline.